Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-12-28
2009-12-22
Vogel, Nancy (Department: 1636)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C536S023400
Reexamination Certificate
active
07635569
ABSTRACT:
Many proteins, when produced recombinantly, suffer from improper processing, folding and lack normal solubility. Modified proteins, including those indicative of disease states, also can have such defects. The present invention is directed to methods of identifying proper and improper protein folding, aberrant processing and/or insolubility. The method relies on the use of two components: a specialized fusion protein and structural complementation. The fusion protein contains sequences from the protein of interest and one portion of a marker protein that, by itself, is not active. A host cell then provides the remainder of the marker protein that serves to “complement” the function of the fused marker protein such that their association restores activity, permitting detection.
REFERENCES:
patent: 5120653 (1992-06-01), Henderson
patent: 6294330 (2001-09-01), Michnick et al.
patent: 6727070 (2004-04-01), Thomas et al.
patent: WO 98/34120 (1998-08-01), None
patent: WO 98/44350 (1998-10-01), None
Abbas-Terki and Picard, “α-Complemented β-galactosidase. An in vivo model substrate for the molecular chaperone heat-shock protein 90 in yeast,”Eur. J. Biochem., 266:517-523, 1999.
Betton et al., “Probing the structural role of an αβ loop of maltose-binding protein by mutagenesis: heat-shock induction by loop variants of the maltose-binding protein that form periplasmic inclusion bodies,”J. Mol. Biol., 262(2):140-150, 1996.
Blackwell and Horgan, “A novel strategy for production of a highly expressed recombinant protein in an active form,”FEBS Lett., 295:10-12, 1991.
Blakely et al., “Epidermal growth factor receptor dimerization monitored in live cells,”Nature Biotech, 18:218-222, 2000.
Bourot et al., “Glycine betaine-assisted protein folding in alysAmutant ofEscherichia coli.,”. J Biol. Chem., 275:1050-1056, 2000.
Brown et al., “Correcting temperature-sensitive protein folding defects,”J. Clin. Invest., 99:1432-1444, 1997.
Bruijn et al., “Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1,”Science, 281:1851-1853, 1998.
Culvenor et al., “Subcellular localization of the Alzheimer's disease amyloid precursor protein and derived polypeptides expressed in a recombinant yeast system,”Amyloid: Int J Exp Clin Invest, 5(2):79-89, 1998.
Dobson, “Protein misfolding, evolution and disease,”TIBS24:329-332, 1999.
Farzaneh et al.,Nucleic Acids Res., 16:11319-11325, 1988.
Foster et al., “Pharmacological rescue of mutant p53 conformation and function,”Science, 286:2507-2510, 1999.
Harper and Lansbury Jr., “Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins,”Annu. Rev. Biochem., 66:385-407, 1997.
Houry et al., “Identification of in vivo substrates of the chaperonin GroEL,”Nature, 402:147-154, 1999.
Huang et al., “NMR structure and mutagenesis of the Fas (APO-1/CD95) death domain,”Nature, 384:638-641, 1996.
Hung et al., “Crystal structure of the ATP-binding subunit of an ABC transporter,”Nature, 396:703-707, 1998.
Huth et al., “Design of an expression system for detecting folded protein domains and mapping macromolecular interactions by NMR,”Protein Sci., 6:2359-2364, 1997.
Johnsson and Varshavsky, “Split ubiquitin as a sensor of protein interactions in vivo,”Proc. Natl. Acad. Sci. USA, 91:10340-10344, 1994.
Kapust and Waugh, “Escherichia colimaltose-binding protein is uncommonly effective at promoting the solubility of polypeptides to which it is fused,”Protein Science, 8:1668-1674, 1999.
King and Sorscher, “Recombinant synthesis of cystic fibrosis transmembrane conductance regulator and functional nucleotide-binding domains,”Methods Enzymol., 292:686-697, 1998.
Ko et al., “The cystic fibrosis transmembrane conductance regulator,”J. Biol. Chem., 268:24330-24338, 1993.
Lee et al., “Effect of the N-terminal hydrophobic sequence of hepatitis B virus surface antigen on the folding and assembly of hybrid β-galactosidase inEscherichia coli,” Eur. J. Biochem., 187:417-424, 1990.
Luzzago and Cesareni, “Isolation of point mutations that affect the folding of the H chain of human ferritin inE. coli,” EMBO J, 8:569-576, 1989.
Maxwell et al., “A simple in vivo assay for increased protein solubility,”Protein Science, 8:1908-1911, 1999.
Nixon and Benkovic, “Improvement in the efficiency of formyl transfer of a GAR transformylase hybrid enzyme,”Protein Engineering, 13(5);323-327, 2000.
Opal and Paulson, “Genetic instabilities and hereditary neurological diseases,”Am J. Hum. Genet., 63(6):1921, 1998.
Papouchado et al., “Expression of properly folded human glutamate decarboxylase 65 as a fusion protein inEscherichia coli,” Eur. J. Biochem., 246:350-359, 1997.
Pelletier et al., “An invivo library-versus-library selection of optimized protein-protein interactions,”Nature Biotech, 17:683-690, 1999.
Qu and Thomas, “Alteration of the cystic fibrosis transmembrane conductance regulator folding pathway,”J. Biol. Chem., 271(13):7261-7264, 1996.
Rao et al., “Rhodopsin mutation G9OD and a molecular mechanism for congenital night blindness,”Nature, 367:639-642, 1994.
Rossi et al., “Monitoring protein-protein interactions in intact eukaryotic cells by beta-galactosidase complementation,”Proc. Natl. Acad. Sci. USA, 94:8405-8410, 1997.
Sugihara and Baldwin, “Effects of 3′ end deletions from Vibrio hrveyi luxB gene on luciferase subunit folding and enzyme assembly: generation of temperature-sensitive polypeptide folding mutants,”Biochemistry, 27:2872-2880, 1988.
Tan and Pepys, “Amyloidosis,”Histopathology, 25:403-414, 1994.
Thomas et al., “Altered protein folding may be the molecular basis of most cases of cystic fibrosis,”FEBS Lett., 312:7-9, 1992.
Thomas et al., “Defective protein folding as a basis of human disease,”TIBS, 20:456-459, 1995.
Valois et al., “Utilisation of the PCA strategy to study the folding of the RBD of raf,”FASEB Journal, 13:A1387, 330, 1999.
Waldo et al., “Rapid protein-folding assay using green fluorescent protein,”Nature Biotechnology, 17:691-695, 1999.
Wang et al., “Expression and purification of the first nucleotide-binding domain an dlinker region of human multidrug resistance gene product: comparison of fusions to glutathione S-transferase, thioredoxin and maltose-binding protein,”Biochem J., 338:77-81, 1999.
Wigley et al., “Protein solubility and folding monitored in vivo by structural complementation of a genetic marker protein,”Nature Biotechnology, 19:131-136, 2001.
Wood et al., “Prolines and amyloidogenicity in fragments of the Alzheimer's peptide β/A4,”Biochemistry, 34(3):724-730, 1995.
Hunt John F.
Stidham Rhesa D.
Thomas Philip Jordan
Wigley William Christian
Board of Regents , The University of Texas System
Fulbright & Jaworski
Trustees of Columbia University in the City of New York
Vogel Nancy
LandOfFree
Protein/solubility folding assessed by structural... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Protein/solubility folding assessed by structural..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protein/solubility folding assessed by structural... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4086666